gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
From MaRDI portal
Publication:6642055
DOI10.1111/RSSC.12263MaRDI QIDQ6642055
Jin Xu, Rongji Mu, Ying Yuan, Sumithra J. Mandrekar, Jun Yin
Publication date: 21 November 2024
Published in: Journal of the Royal Statistical Society. Series C. Applied Statistics (Search for Journal in Brave)
Related Items (6)
Biomarker-based precision dose finding for immunotherapy combined with radiotherapy ⋮ DROID: dose-ranging approach to optimizing dose in oncology drug development ⋮ A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications ⋮ Early completion of phase I cancer clinical trials with Bayesian optimal interval design ⋮ Commentary on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies ⋮ Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
This page was built for publication: gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6642055)
